Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche for the buyout

<< Previous

Bullboard Posts

Next >>

Post by CaseyLon Oct 27, 2023 5:29pm

432 Views

Post# 35705080

Roche for the buyout

Arguably pancreatic cancer is the most unique on going trial. If there's great success, it's the one that stands out. There hasn't been much success or improvement with pancreatic cancer in too many years. With that being said, we can't forget the mega parade float with PanCan. I'm sure things are quite intense as far as business aspects. I'm putting my money on Roche.

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for Nov. 14, 2024